Haptoglobin, Mixed Type [9087-69-8]

Athens Research

Haptoglobin, Mixed Type [9087-69-8]

9

ELISA, Protein Chemistry, Inflammation, Sickle Cell Anemia, Glycosylation, Stroke, Central Nervous System Injury, Diabetes, Cardiovascular Disease, In Vitro Diagnostic, Iron Metabolism, Cancer

Research Use Only

≥95% by SDS-PAGE

Haptoglobin

Haptoglobin is a major acute-phase plasma glycoprotein present at concentrations of 100–300 mg/dL, primarily synthesized in the liver. Its central function is to bind free hemoglobin released during red blood cell breakdown, thereby preventing iron loss through the kidneys and reducing hemoglobin-driven oxidative tissue damage. This hemoglobin–haptoglobin complex is rapidly cleared by macrophages via the CD163 receptor, facilitating iron recycling and modulating antioxidant and anti-inflammatory pathways. Haptoglobin also influences immune responses, interacting with neutrophils, lymphocytes, and dendritic cells to regulate inflammation and adaptive immunity. Humans exhibit three main haptoglobin phenotypes-Hp 1-1, Hp 2-1, and Hp 2-2-arising from genetic polymorphisms. Hp 1-1 demonstrates the highest hemoglobin-binding and antioxidant efficiency, while Hp 2-2 is least effective, which may explain its association with increased risk and severity of conditions such as cardiovascular disease, diabetes, and epilepsy. Notably, the Hp 2-2 phenotype is linked to poorer outcomes in coronary artery disease and more frequent epilepsy attacks, likely due to reduced antioxidant protection in neural tissues. Clinically, haptoglobin serves as a sensitive biomarker for hemolytic anemia, liver function, and as a potential prognostic marker in cancer and inflammatory diseases. Therapeutically, recombinant haptoglobin is being explored for treating hemolysis-related complications and as a neuroprotective agent following subarachnoid hemorrhage.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -20° C

41116100